ORION CORPORATION
STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS
6 March 2026 at 16.00 EET
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly and indirectly by BlackRock, Inc. and its funds increased on 5 March 2026 above five (5) per cent of Orion Corporation’s total shares.
Total positions of BlackRock, Inc. and its funds subject to notification:
% of shares and voting rights | % of shares and voting rights through financial instruments | Total of both in % (points A + B) | Total number of shares and voting rights of issuer | |
Resulting situation on the date on which threshold was crossed or reached | 5.02% shares | 0.00% shares | 5.02% shares | 141,134,278 shares |
Position of previous notification (if applicable) | 4.99% shares | 0.00% shares | 5.00% shares |
Notified details of the resulting situation on the date on which the threshold was crossed:
Point A: Shares and voting rights:
Class/type of shares | Number of shares and voting rights | % of shares and voting rights | ||
Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | |
FI0009014377 | 7,090,149 shares | 5.02% shares | ||
POINT A SUBTOTAL | 7,090,149 shares | 5.02% shares | ||
Point B: Financial instruments according to SMA 9:6a:
Type of financial instrument | Expiration date | Exercise / Conversion Period | Physical or cash settlement | Number of shares and voting rights | % of shares and voting rights |
American Depositary Receipt (US68628Y1047) | N/A | N/A | Physical | 200 shares | 0.00% shares |
CFD | N/A | N/A | Cash | 4,574 shares | 0.00% shares |
POINT B SUBTOTAL | 4,774 shares | 0.00% shares |
Orion Corporation
Liisa Hurme | Mikko Kemppainen |
Contact person:
Tuukka Hirvonen, Investor Relations, Orion Corporation
tel. +358 10 426 2721
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
www.orionpharma.com
Orion Pharma is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals as well as active pharmaceutical ingredients, combining our trusted expertise with continuous innovation. We have an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by us are used to treat cancer, respiratory diseases and neurological diseases, among others. In 2025 our net sales amounted to EUR 1,890 million, and we employ about 4,000 professionals worldwide, dedicated to building well-being.